1. ������ѧ������ɽҽԺƤ����
2. �Ϻ���ɽҽԺƤ����

��ժҪ�� ��άӲ����ϵͳ��Ӳ������һ����Ҫ��������ij���άϸ����������Ľ�ԭ��ά����Ƥ�����������ٵ���άӲ����Ӱ�컼�ߵ������������������»�������������ȱ����Ч������ά���ķ������䷢�����Ƽ����Ʒ������һ�����о�����������Ҫ����άӲ�������������֯�ڸ���ϸ���쳣�����ڰе��������֢��Ӧ�����ƴ���ά�����ӡ����ڱ���Ŵ��ź�ת����������̬�γ�;���ȷ���Կ���ά���İ���������������

Xin Chongmei, Cui Xiangxiang, Li Ming. Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China Corresponding author: Li Ming, Email: li.ming@zs-hospital.sh.cn ��Abstract�� Fibrosis is a key feature of systemic sclerosis ��SSc�� and arises from excessive production of collagen fibers by pathologically activated fibroblasts. It can affect the skin and many internal organs, negatively influence the quality of life, and even threaten the life of patients. Since effective therapies for fibrosis are unavailable, further studies are still needed to elucidate the pathogenesis of and to evaluate treatment strategies for, SSc. This review mainly focuses on some therapies targeting various cellular abnormalities and regulatory factors during fibrosclerosis, which can counteract fibrosis by blocking inflammatory pathways, inhibiting profibrotic growth factors, modulating epigenetic signaling transduction, and interfering with morphogenic pathways.